---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Phase of product development"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Phase of product development. Topics: Regulatory status: Submission planned; registrational phase 3 EMERGE trial ongoing, with top-line results expected in the second half of 2028; Investigational status; Planned update to EMERGE top-line guidance by the end of 2027; Orphan drug designation for myasthenia gravis, May 2026; 6 further topics. 10 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; registrational phase 3 EMERGE trial ongoing, with top-line results expected in the second half of 2028

> “In June 2026, we announced the initiation of the Phase 3 registrational EMERGE trial of claseprubart in gMG. We expect to report top-line results from this trial in the second half of 2028.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in 2H’28”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “EMERGE is a global Ph. 3 trial evaluating Q4W and Q2W S.C. claseprubart in AChR+ gMG; top-line data 2H’28”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Investigational status

> “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-2.1.1-4"></a>

### Planned update to EMERGE top-line guidance by the end of 2027

> “Claseprubart Updated Ph. 3 EMERGE top-line guidance (YE’27)”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-5"></a>

### Orphan drug designation for myasthenia gravis, May 2026

> “On May 1, 2026, claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Orphan Drug Designation granted: Claseprubart was granted Orphan Drug Designation by the FDA for the treatment of Myasthenia Gravis.”

Source: [Dianthus Therapeutics (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm)

<a id="topic-2.1.1-6"></a>

### Fast track or breakthrough therapy designation for generalized myasthenia gravis

No evidence found.

<a id="topic-2.1.1-7"></a>

### Phase 2 MaGic trial initiated after FDA IND clearance, February 2024

> “today announced the initiation of the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis. The initiation follows U.S. Food and Drug Administration (FDA) clearance of the Phase 2 Investigational New Drug (IND) application for DNTH103.”

Source: [Dianthus Therapeutics (2024a)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-2-magic-trial)

<a id="topic-2.1.1-8"></a>

### Phase 2 MaGic top-line results, September 2025

> “Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13”
> “we are planning for an end-of-Phase 2 meeting with the FDA to align on the proposed design of a Phase 3 trial for claseprubart in Myasthenia Gravis that investigates both 300mg Q2W and 300mg Q4W doses vs.”

Source: [Dianthus Therapeutics (2025b)](https://www.sec.gov/Archives/edgar/data/1690585/000119312525197751/d933929dex991.htm)

<a id="topic-2.1.1-9"></a>

### End-of-phase 2 meeting with the FDA, first quarter of 2026

> “In September 2025, we reported positive top-line results from the Phase 2 MaGic trial of claseprubart for patients with gMG and subsequently held an end-of-Phase 2 meeting with the FDA in the first quarter of 2026.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “No ANA screening exclusion criteria or routine ANA testing during RCT or OLE, inclusion criteria of MG-ADL of ≥6 and QMG of ≥10, and 17-week S.C. treatment period per alignment with FDA”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.1-10"></a>

### Phase 3 EMERGE trial initiated, June 2026

> “today announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG).”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “Study Start (Actual) 2026-06-29”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-2.1.1-11"></a>

### FDA written feedback on antinuclear antibody screening and drug-induced lupus, March 2026

> “Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs”
> “Removal of routine ANA testing during claseprubart clinical trials”
> “Reclassification of the hypothetical risk of systemic lupus erythematosus ("SLE") to drug-induced lupus ("DIL")”
> “In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="topic-2.1.1-12"></a>

### Other indications in development

> “Dianthus is building a neuromuscular franchise with claseprubart and expects to report top-line results from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in December ’26, report top-line results from the Phase 3 CAPTIVATE trial Part A in CIDP by YE’27 and from Part B by YE’28, and report top-line results from the Phase 3 EMERGE trial in generalized Myasthenia Gravis in 2H’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
